Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service skin substitutes & wound grafts cases in Utah: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (246 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 10 | 2,295 | 41% |
| 2020 | 12 | 4,017 | 44% |
| 2021 | 15 | 4,856 | 48% |
| 2022 | 19 | 5,778 | 51% |
| 2023 | 24 | 5,686 | 54% |
| 2024 | 18 | 5,940 | 57% |
| 2025 from claims | – | 3,618 3,321–3,828 | 59% |
| 2026 forecast | – | 3,890 3,422–4,489 | 60% |
| 2027 forecast | – | 4,183 3,576–4,985 | 61% |
| 2028 forecast | – | 4,497 3,752–5,506 | 62% |
| 2029 forecast | – | 4,832 3,947–6,060 | 62% |
| 2030 forecast | – | 5,191 4,158–6,652 | 63% |
Application of cellular and tissue-based products to wounds; the loudest category in Open Payments. Professional codes (what the surgeon bills): CPT 15271, 15273, 15275, 15277.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 82% of the cases CMS names in Utah; 10 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 23% hospital outpatient, 77% office. The share outside the hospital has moved +22 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Hospital outpatient | Office |
|---|---|---|
| 2026 · ~3,900 | ~860 | ~3,000 |
| 2027 · ~4,200 | ~910 | ~3,300 |
| 2028 · ~4,500 | ~970 | ~3,500 |
The forecast’s cases at the projected mix.
The mix is steady: the trend moves no setting by a point or more by 2028.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 313 | 86,283+22%/yr | +22%/yr | 15.6 | 83% | 134,700 in 2030+7.7%/yr |
| Arizona | 83 | 15,125+16%/yr | +16%/yr | 12.6 | 85% | 26,900 in 2030+10%/yr |
| Nevada | 52 | 12,513+43%/yr | +43%/yr | 26.2 | 72% | 17,600 in 2030+5.9%/yr |
| Washington | 21 | 7,289+5.2%/yr | +5.2%/yr | 5.9 | 78% | 11,800 in 2030+8.4%/yr |
| Colorado | 27 | 6,374+23%/yr | +23%/yr | 7.8 | 82% | 11,000 in 2030+9.5%/yr |
| Oregon | 20 | 3,597+11%/yr | +11%/yr | 5.0 | 89% | 4,970 in 2030+5.5%/yr |
| Idaho | 11 | 2,190+7.1%/yr | +7.1%/yr | 6.8 | 51% | 4,080 in 2030+11%/yr |
| New Mexico | 9 | 2,075+17%/yr | +17%/yr | 5.6 | 92% | 2,610 in 2030+3.9%/yr |
| Montana | 9 | 1,642+11%/yr | +11%/yr | 6.7 | 62% | 1,670 in 2030+0.3%/yr |
| Hawaii | 3 | 546+7.6%/yr | +7.6%/yr | 2.4 | 74% | 1,080 in 2030+12%/yr |
| Wyoming | 0 | 397+25%/yr | +25%/yr | 3.2 | 90% | 650 in 2030+8.5%/yr |
| Alaska | 1 | 290−8.4%/yr | −8.4%/yr | 2.4 | 29% | 500 in 2030+9.7%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Debridement & negative-pressure wound therapy | 146 | 24,0660%/yr | 0%/yr | 104.71.1× | 45% | 29,100 in 2030+3.2%/yr |
| Bone graft & orthobiologics | 7 | 330−1.7%/yr | −1.7%/yr | 1.51.9× | 5% | 420 in 2030+4.1%/yr |
Skin substitutes & wound grafts in every state, and its device makers · Every procedure market in Utah · Every state · Compare with California
Integra LifeSciences leads with 49% of company spending on these surgeons in 2025, −30 pts on 2024.
In 2025, 27 companies reported engagement with Utah’s surgeons worth $191K in consulting, speaking, meals and travel tied to these products, about $11K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 37 clearances and approvals in the category, 13 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.